A supercharged oligonucleotide therapeutic has proven potential for maximizing the advantages of a genetic remedy for Duchenne muscular dystrophy (DMD) in preclinical research.
The research, in PNAS, establishes the worth of those bifunctional or bipartite antisense oligonucleotides (ASOs)—quick, artificial, single-stranded nucleic acid analogs comprising an antisense portion with a regulatory tail that recruits splicing suppressors—in RNA-targeted therapeutics.
DMD is an X-linked recessive progressive muscle situation that normally solely impacts boys and causes muscle weak spot and degeneration as a consequence of mutations in a gene encoding the dystrophin protein.
Utilizing their superior ASO approach, the researchers have been capable of effectively skip mutated exons within the DMD gene and restore dystrophin expression in muscle tissues from mouse fashions of the illness.
The protection profile was deemed favorable in mouse and cynomolgus monkey fashions.
“These outcomes point out that the bipartite-ASO know-how is an efficient platform for exon-skipping therapeutics,” the researchers reported.
Exon-skipping ASOs have already been authorized to deal with DMD, however typical designs usually lack the efficiency wanted for strong therapeutic outcomes.
Lead researcher Pengchao Feng, from Nanjing Antisense Biopharm, and crew due to this fact developed a bipartite-ASO know-how utilizing a brief 5’-splice website decoy (5D) sequence that promoted environment friendly exon skipping.
The straightforward however efficient 5D-ASO approach makes use of a brief tail sequence to boost the splicing repression exerted by an antisense half.
The tail is carried by the antisense half to an exon of interested in a goal pre-messenger RNA. Right here, it interferes with recognition of the exon’s 5’-splice website and markedly improves exon skipping in contrast with ASOs with out such tails.
The 5D-ASO method was capable of effectively skip mutated exons within the DMD gene and restore dystrophin expression within the muscle tissues of a mouse mannequin of the muscular dystrophy.
Specifically, an 8-nt tail connected to the 5′ finish of antisense sequences concentrating on DMD exon 51 robustly enhanced its skipping in skeletal and cardiac muscle tissues, with environment friendly dystrophin restoration in genetically modified mice after systemic administration.
“We confirmed 5D-ASO’s broad applicability with numerous genes and exons,” the researchers reported.
“Furthermore, utilizing DMD exon 51 for instance, we demonstrated that this technique is robustly efficient in vivo.”
They added: “The lead ASO confirmed marked exon skipping and a good security profile in cynomolgus monkeys, highlighting the method as a robust software in antisense therapeutics.”
